Celltrion Will Exhibit Drug Pipeline in Milan
The firm will showcase its research in cancer and metabolic disease to potential partners this October.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you believe attending international industry trade shows is an effective way for companies to grow?
Celltrion will exhibit at the 2026 World Pharmaceutical and Biotechnology Exhibition in Milan, Italy, from October 6 to 8, 2026. This appearance marks the company's fifth consecutive year hosting a solo booth at the event.
Why it matters
The company aims to expand its drug pipeline for anticancer, obesity, and metabolic treatments through international collaboration. It is also targeting new customers for its contract development and manufacturing organization services.
Celltrion will deploy 6 corporate representatives to manage its on-site programming at the 2026 exhibition. The company currently focuses its research on anticancer, obesity, and metabolic disease treatments.
The players
Celltrion
A biotechnology firm focused on developing anticancer, obesity, and metabolic disease drugs and providing CDMO services.
The details
Celltrion utilizes its presence at the World Pharmaceutical and Biotechnology Exhibition to facilitate technical discussions and promote its contract development and manufacturing organization (CDMO) services. CDMOs are companies that provide outsourced drug development and manufacturing to the pharmaceutical industry. Representatives will conduct on-site programs to detail their current research pipeline and identify potential industrial partners.
Timeline
Celltrion began its annual solo booth participation in 2022.
The company confirmed its participation on September 29, 2026.
The World Pharmaceutical and Biotechnology Exhibition runs from October 6 to 8, 2026.
The Tech Race
Celltrion utilizes the World Pharmaceutical and Biotechnology Exhibition to signal its competitive positioning against other international CDMO providers. This event serves as a central venue for firms to secure and expand their contract manufacturing pipelines.
The firm’s expansion of its drug pipeline aims to accelerate the availability of new anticancer and metabolic treatments for global patients. Professionals in the industry should watch for partnership announcements emerging from the Milan event.
The takeaway
Celltrion is deepening its focus on metabolic and anticancer drug development to capture a larger share of the global CDMO market. Industry participants should monitor the outcomes of the Milan exhibition for new collaboration agreements.
What happens next
The exhibition will take place in Milan from October 6 to 8, 2026, where the company's progress in metabolic and anticancer research will be on display.
Further reading
For more on the latest research and industry partnerships, visit the Biotech section.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you believe attending international industry trade shows is an effective way for companies to grow?
